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Abstract
Introduction. In patients with Y-chromosome in the karyotype, partial gonadal dysgenesis and disorders of male 
reproductive sex organs development are usually resected in childhood because of the high risk of germ cell 
tumours (GCT). In patients with Y-chromosome, complete gonadal dysgenesis and female genitalia gonadec-
tomy is performed markedly later. However, due to the relatively low number of adult patients with preserved 
dysgenetic gonads, the true risk of neoplasm is unknown. The aim of the study was to evaluate the prevalence 
of neoplasia in dysgenetic gonads of children and adults with Y-chromosome in a retrospective study.
Material and methods. A review of medical documentation of 94 patients with disorders of sex development 
(DSD), Y-chromosome and gonadal dysgenesis (GD), aged 1.2–32 years (47 prepubertal, 1.2–10 years; 
47 pubertal/adult, 13–32 years), was conducted. Serum levels of follicle-stimulating hormone (FSH), luteinizing 
hormone (LH) and testosterone were determined. Bilateral gonadectomy was performed in 73.4% of patients, 
and unilateral gonadectomy with biopsy of the contralateral gonad in 26.4%. All gonadal tissues were subjected 
to immunohistochemical evaluation with antibodies against PLAP and OCT3/4 (markers of malignant germ cells, 
but also foetal multipotent germ cells), while gonads of prepubertal patients were examined by c-KIT, as well. 
Results. Streak gonads were identified on both sides (complete GD) in 30.8%, a streak gonad on one side and 
an underdeveloped testis on the other (asymmetric GD) in 38.3%, and underdeveloped testicular structure on 
both sides (partial GD) in 30.8% of cases. Germ cell neoplasia was found in 53.2% of patients (51.1% in children, 
55.3% in pubertal/adults). Invasive GCT were identified in 11.7% of cases, of which 90.9% were in pubertal/adult 
patients. Other neoplastic lesions included gonadoblastoma (16% prevalence) and testicular carcinoma in situ 
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(25.5%). In younger patients FSH serum levels were increased in 81% of cases (mean 2.82 ± 2.18 IU/L), while 
LH in 58% (mean 1.82 ± 1.69 IU/L). Hypergonadotropic hypogonadism was diagnosed in most of the pubertal/ 
/adult patients (mean FSH 54.2 ± 23.3 IU/L, mean LH 21.7 ± 12.1 IU/L, mean testosterone 5.5 ± 4.5 nmol/L).
Conclusions. Dysgenetic gonads in patients with Y chromosome have a high risk of germ cell neoplasia (ca. 
50%). If they are preserved until puberty/early adulthood, they may develop overt, invasive GCT. The gonads 
also have poor hormonal activity (hypergonadotropic hypogonadism) in most of the pubertal/adult patients. Each 
of these cases must be considered individually and a decision to remove the gonad or not should be based on 
the comprehensive analysis of the phenotype by a multidisciplinary team of specialists in consultation with the 
patient and the parents. If dysgenetic gonads are not resected in childhood, these patients need careful ongoing 
follow-up examination, including biopsy and histopathological evaluation. (Folia Histochemica et Cytobiologica 
2015, Vol. 53, No. 3, 218–226)
Key words: testis; gonadal dysgenesis; testicular carcinoma in situ; gonadoblastoma; germ cell tumours; hyper-
gonadotropic hypogonadism
Introduction
Gonadal dysgenesis (GD) is a term used to describe 
the incomplete formation (organogenesis) of gonads, 
testes or ovaries during embryogenesis [1, 2]. The 
origin of this condition may be genetic or environ-
mental [3–6].
In patients with the Y-chromosome, or Y-chromo-
some-specific sequences in the genotype including the 
presence of the SRY gene (sex-determining region Y), 
dysgenetic gonads are histologically categorised as: 
1) bilateral streaks of an ovarian-like cortical stroma 
(complete or pure GD); 2) a streak on one side and 
testis-like stroma on the other (asymmetric or mixed or 
combined GD); 3) bilateral testes with incomplete or-
ganogenesis (partial GD) [7, 8]. In testicular dysgenesis, 
germ cells are absent or spermatogenesis is arrested at 
the level of foetal gonocytes or spermatogonia, Sertoli 
cells frequently remain immature and the adult type 
of Leydig cells rarely appears [7–11]. Disturbances in 
the maturation of these testicular somatic cells lead to 
disorders of male internal and external reproductive 
sex organs development. Absent or decreased secre-
tion of testosterone by foetal Leydig cells results in 
differentiation disorders of the external and internal 
male sex organs. Disturbed secretion of antimüllerian 
hormone (AMH) by Sertoli cells is associated with 
the persistence of Müllerian ducts and the presence 
of female internal sex organs in patients with the male 
genetic sex. A further clinical consequence of deterio-
rated testicular development is hypergonadotropic 
hypogonadism observed from the pubertal period of 
life [10, 12, 13]. These patients are referred to the group 
of disorders of sex development (DSD) and classified as 
sex chromosomal DSD or 46,XY DSD or 45,X/46,XY 
DSD according to the karyotype [14].
All forms of testicular GD are accompanied by 
an increased risk of germ cell neoplasia [15, 16]. 
Neoplastic lesions appear as overt, invasive germ cell 
tumours (GCT), which can be either seminomatous 
or non-seminomatous, and usually develop in young 
adults [17]. Preinvasive testicular carcinoma in situ 
(CIS, or intratubular germ cell neoplasia unclassified 
— IGCNU or testicular intraepithelial neoplasia — 
TIN) [17, 18] is seen not only in the testes of adult 
men, but also in the gonads of prepubertal children 
[7–9, 11, 19–21]. Other germ cell neoplastic lesions 
include the sex cord-derived tumours, gonadoblasto-
ma (GB) and unclassified mixed germ cell-sex cord 
stromal tumours found mainly in testes with profound 
developmental defects [10, 22, 23]. 
Underdeveloped testes (in partial or asymmetrical 
GD) in patients with Y-chromosome, if early diagnosed, 
are frequently resected at prepuberty due to their poten-
tial for presumptive GCT development. However, the 
procedure is controversial, as some of these gonads may 
have adequate hormonal function and normal sperma -
togenic cells, and may never develop GCT [10, 11, 24]. In 
patients with Y-chromosome and complete GD preven-
tive gonadectomy is performed markedly later because of 
female phenotype. Nevertheless, also in these cases the 
removal of gonads is the matter of criticism. The true risk 
of neoplasia in GD is in fact unknown because of the rela-
tively low number of adult patients with preserved gonads.
The aim of our study was to determine the preva-
lence of neoplasia in dysgenetic gonads in children 
and adults with the Y-chromosome in their genotype.
Material and methods
Patients and clinical data. The study was performed with 
the approval of the Bioethical Committee of the Medical 
University of Lodz (no RNN/28/10/KE). 
A review was conducted of the medical documentation 
of DSD patients diagnosed and treated from 1983 to 2013 in 
the centres of Paediatric Endocrinology, Paediatric Urology 
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and Genetics in Lodz and Warsaw, Poland. Ninety-four pa-
tients, aged 1.2–32 years, were included. External sex organs 
were qualified as female or ambiguous (undervirilised male 
or virilised female). Ultrasonography, later confirmed by 
genitography and abdominal surgery, revealed all patients 
to have the remnants of Müllerian ducts. The gonads were 
located mainly in the minor abdominal cavity or in some 
cases in the upper segment of the inguinal canal. All patients 
possessed the Y-chromosome in either 46,XY (71.3%) 
or a mosaic complement (i.e. 45,X/46,XY, 45,X/47,XXY, 
45,X/46,XY/47,XXY — 28.7%). 
Bilateral gonadectomy was performed in 73.4% of pa-
tients, unilateral with the biopsy of the contralateral gonad 
in 26.4%. The age of histopathological evaluation of gonads 
was as follows: 1.2–10 years (median 3.0) — 50%, 13–32 
years (median: 17.0) — 50%. Gonadal tissues were fixed in 
formalin (mostly in younger group) or in Bouin’s fixative 
(mostly in older group) and stored in paraffin. 
Serum levels of follicle-stimulating hormone (FSH), 
luteinizing hormone (LH) and testosterone were determined 
shortly before gonadectomy. In most patients chemilu-
minometric immunoassay was used, while in some cases 
radioimmunological or immunoenzymatic. The following 
were taken as reference values for prepubertal children — 
FSH: 0.22–1.92 IU/L, LH: 0.02–0.42 IU/L and testosterone: 
< 0.1–0.35 nmol/L. The corresponding values for healthy 
adult men were FSH: 1.70–10.35 IU/L, LH: 1.54–7.00 IU/L 
and testosterone: 12.25–33.95 nmol/L [25].
Histology and immunohistochemistry. The gonads were cut 
into sections 5 µm thick, and stained with haematoxylin and 
eosin (H & E). Histological examination was then performed 
with the use of an Eclipse E600 light microscope (Nikon, 
Tokyo, Japan). 
Immunohistochemical staining for foetal multipotent 
germ cells (gonocytes)/malignant germ cells, was carried out 
in all patients using monoclonal antibodies against placental 
like alkaline phosphatase (PLAP) (Novocastra Laboratories, 
Newcastle, UK), and against octamer transcription factor 
3/4 (OCT3/4) (Santa Cruz Biotechnology Inc., Dallas, Texas, 
USA). Polyclonal antibody against the c-Kit proto-oncogene 
(c-KIT, Santa Cruz Biotechnology Inc.) was performed only 
in the gonads of prepubertal children. The primary antibody 
was diluted to 1:25 (PLAP), 1:200 (OCT3/4) or 1:50 (c-KIT) 
in 0.05 M Tris-buffered saline, pH 7.4. For the qualitative 
detection of antigens in fixed paraffin-embedded tissue 
sections, the Impress polymerized reporter enzyme stain-
ing system (Vector Laboratories, Peterborough, UK) was 
used for PLAP and OCT3/4, and the Novocastra Novolink 
Polymer Detection System (Leica Biosystems, Nussloch, 
Germany) for c-KIT. Five histological sections were exam-
ined for each gonad.
A testicular CIS (a part fixed in formalin and part in 
Bouin’s fluid) from an adult patient served as a positive 
control for PLAP, OCT3/4 and c-KIT. For the negative 
control, the primary antibodies were replaced with 0.05 M 
Tris-buffered saline, pH 7.4.
Statistical analysis. Basic statistical analyses (mean, stand-
ard deviation, median) were performed using Statistica 8.0 
software (StatSoft, Krakow, Poland). Confidence interval 
was set at 95%.
Results
The group of patients was divided into two subgroups: 
1) prepubertal patients (age: 1.2–10 years) and 2) pu- 
bertal/adult patients (13–32 years). All patients 
from the younger group presented Tanner stage I of 
puberty, while the older patients presented various 
stages of secondary sexual characteristics. The start 
of puberty in the older group was confirmed by the 
activity of the hypothalamus-pituitary axis (increased 
FSH and LH serum levels), and the results in both, 
young and old, subgroups are given in Table 1. FSH 
levels were higher in 81% of younger patients and all 
pubertal/adult patients compared to the correspond-
ing normal values. LH was elevated in 58% of younger 
patients and in 83.8% of pubertal/adult patients. 
Testosterone levels were at prepubertal values in all 
Table 1. Gonadotropin and testosterone concentration in the blood of patients with gonadal dysgenesis and Y-chromosome
Age group (years) Age (years) FSH [IU/L] LH [IU/L] Testosterone [nmol/L]
1.2–10
n = 47
Mean ± SD
Median
Range
4.14 ± 2.38
3.0
1.17–10.0
2.82 ± 2.18
2.2
0.1–8.37
1.82 ± 1.69
1.34
0.30–5.6
0.44 ± 0.39
0.35
0.01–1.86
Normal prepubertal 
values
Range 0.22–1.92 0.02–0.42 < 0.1–0.35
13–32
n = 47
Mean ± SD
Median
Range
18.09 ± 4.39
17.00
13.00–32.00
54.24 ± 23.26
57.00
17.00–105.00
21.75 ± 12.08
23.00
4.4–50.00
5.55 ± 4.46
4.80
0.38–13.40
Normal adult values Range 1.70–10.35 1.54–7.00 12.25–33.95
Range provides 95% confidence interval. Abbreviations: n — number of cases; FSH — follicle-stimulating hormone; LH — luteinizing hormone
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children, and either low (80.7%) or normal (19.3%) 
in pubertal/adult patients.
All of the gonads displayed features of dysgenesis 
under histopathological evaluation (Figure 1). Of 
the whole group, 29 (30.85%) were patients with 
complete GD, 36 (38.30%) with asymmetric GD 
and 29 (30.85%) with partial GD. In the whole do - 
cumentation we found 6 patients with ovotestes. 
Three patients were not included to this study be-
cause were younger than 1 year. In the next 3 patients 
ovocytes were not found in the wider than normal 
cortical part of gonad, and, therefore, ovotestis was 
not recognised, but partial GD.
The numbers of different types of germ cell ne-
oplasia found in the dysgenetic gonads are given in 
Table 2. Diagnoses of GB and overt GCT were based 
on specific histological features [22]. Overt GCT 
included seminomatous (one 7-year-old patient and 
4 pubertal/adults) and non-seminomatous (1 — imma-
ture teratoma, 5 — mixed GCT) tumours. The mixed 
GCT contained elements of embryonal carcinoma, 
yolk sac tumour, teratoma and seminoma.
CIS was indicated not only by histological features, 
but also by positive immunohistochemical reactions 
with antibodies against PLAP and OCT3/4 in all go-
nads, as well as against c-KIT in those of prepubertal 
Figure 1. Dysgenetic gonad of prepubertal child (A, C, E) and adult men (B, D) with disorders of sex development. 
Positive reaction with antibodies against PLAP (A, B), OCT3/4 (C, D), c-KIT (E) in germ cells. The brownish staining of 
cytoplasm (PLAP and c-KIT) and nuclei (OCT3/4) confirms the diagnosis of testicular carcinoma in situ. Note the wide 
intertubular spaces specific for dysgenetic testes structure. Magnification × 200.
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children (Figure 1). Only samples which expressed 
these immunohistochemical diagnostic markers, and 
displayed a distinctive pattern of atypical germ cells 
with the characteristics of the gonocytes (bigger than 
normal spermatogonia, large cytoplasm, hyperchro-
matic nuclei with prominent nucleoli, big irregular 
clumps of heterochromatin), and were located near 
the basal membrane in the seminiferous epithelium 
were classified as neoplastic CIS cells. 
The total risk of germ cell neoplastic lesions 
was 51.1% (24/47) in prepubertal children, 55.3% 
(26/47) in pubertal/adult patients and 53.2% (50/94) 
in the whole group. The risk of neoplasm was 55.2% 
(16/29) (children — 4/6, 66.7%, pubertal/adults — 
12/23, 52.2%) in patients with the complete GD, 
41.7% (15/36) (children — 7/21, 33.3%, pubertal/ 
/adults — 8/15, 53.3%) in those with asymmetric GD 
and 65.5% (19/29) (children — 13/20, 65%, pubertal/ 
/adults — 6/9, 66.7%) in those with partial GD. Overt 
GCT were revealed in 11.7% (11/94) of cases, most 
of them (90.9%) in pubertal/adult patients with all 
types of GD. GB was found in 16% (15/94) of patients 
(children — 6/47, 12.8%, pubertal/adults — 9/47, 
19.1%), while CIS in 25.5% (24/94) (children — 17/47, 
36.2%, pubertal/adults — 7/47, 14.9%). GB was the 
most prevalent in patients with complete GD (11/15, 
73.3%), while CIS was most common in patients with 
partial GD (15/24, 62.5%). In asymmetric GD the 
neoplastic lesions were found only in underdeveloped 
testes.
Besides the germ cell neoplasia, sertolioma com-
posed of cells with features of foetal/prepubertal Ser-
toli cells was identified in 2 (2.1%) adult patients, one 
in a streak gonad and one in a patient with partial GD.
Discussion
Testicular cancer represents 1–1.5% of male neo-
plasms, with an incidence of 0.3–1% new cases per 
year in the general population of European countries, 
mainly in young adults [26–29]. Although the risk of 
GCT in dysgenic gonads in patients with Y-chromo-
some is known to be high, the precise risk has not been 
determined. Based on an epidemiological analysis of 
GCT established and suspected risk factors, Dieck-
mann and Pichlmeier [15] attribute levels of evidence 
to each of the putative risk factors. GD was assessed 
as high risk (up to 25% cumulative risk) but because 
of rare, heterogenous cases and small case series 
which were regarded as only level IV in the formal 
hierarchy of evidence. They established also that risk 
factor with the highest level of evidence (level I) is the 
presence of undescended testes (cryptorchidism), in 
which a cause might be GD [30, 31]. Our previous 
study found that adult patients with cryptorchidism 
may demonstrate the histological features of GD, 
Table 2. Germ cell neoplasia in dysgenetic gonads of patients with Y-chromosome
Group Gonad GB
n
CIS
n
GCT
n
Total
n (%)
Total in GD types
n (%)
Age: 1.2–10 years
Complete GD
n = 6
One 1 0 1 2 (33.3)
4 (66.7)
Both 2 0 0 2 (33.3)
Asymmetric GD
n = 21
One 1 6 0 7 (33.3)
7 (33.3)
Both 0 0 0 0
Partial GD
n = 20
One 0 2 0 3 (15.0)
13 (65.0)
Both 1 9 0 10 (50.0)
Total n (%) 6 (12.8) 17 (36.2) 1 (2.1) 24 (51.1)
Age: 13–32 years
Complete GD
n = 23
One 3 0 4 7 (30.4)
12 (52.2)
Both 5 0 0 5 (21.7)
Asymmetric GD One 1 3 4 8 (53.3)
8 (53.3)
n = 15 Both 0 0 0 0
Partial GD
n = 9
One 0 2 2 4 (44.4)
6 (66.7)
Both 0 2 0 2 (22.2)
Total n (%) 9 (19.1) 7 (14.9) 10 (21.3) 26 (55.3)
Abbreviations: n — number of cases; GB — gonadoblastoma; GD — gonadal dysgenesis; CIS — testicular carcinoma in situ; GCT — germ cell tumour
223Neoplasia in testicular dysgenesis
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2015
10.5603/FHC.a2015.0021
www.fhc.viamedica.pl
i.e. decreased seminiferous tubule diameter, thicker 
tubular membrane, increased intertubular space or 
the presence of tubules with immature Sertoli cells, 
and an increased incidence of germ cell neoplastic 
lesions (11.1%) [32]. 
Looijenga et al. [33] classify the risk for GCT 
development in the gonads of patients with DSD 
and Y-chromosome into high, intermediate, low and 
unknown levels. However, this analysis was based on 
a limited number of studies. Patients with GD, those 
who were positive for testis-specific Y-encoded pro-
tein (TSPY) and those with intra-abdominal gonads 
were included in the high-risk group (risk 15–60% 
based on the literature) [9, 12, 33]. In our patients, 
as the dysgenetic gonads were located in the minor 
abdominal cavity or in the upper segment of the 
inguinal canal, a high risk of GCT was suspected. 
Unfortunately, TSPY could not be identified in go-
nads fixed in Bouin’s fixative. Nevertheless, germ cell 
neoplasia could be recognised undoubtedly in about 
50% of pubertal/adult patients with GD. Moreover, 
the incidence of germ cell neoplasia seemed to be 
similar in younger subgroup. 
CIS cells were more frequent in the younger 
(36.2%) then the older subgroup (14.9%). However, 
there are difficulties in the diagnosis of malignant germ 
cells in children. CIS cells originate from develop - 
mentally arrested foetal germ cells (gonocytes) [4, 
16, 34]. A number of studies show that the arrest of 
germ cell differentiation is the key event, which may 
be followed by malignant transformation and invasive 
GCT development, usually occurring in young adults 
[16, 32, 35]. CIS cells have some morphological fea-
tures of gonocytes, but also display a series of antigens 
present normally in the foetal period of life, some of 
them up to the first year after birth [35, 36]. After this 
age, foetal antigen expression is used as an immuno-
histochemical marker of malignant germ cells. PLAP, 
OCT3/4 and c-KIT have been proposed as the best 
immunohistochemical markers for malignant germ 
cells [37, 38]. While there is no doubt as to their signi-
ficance in pubertal or adult men, this is not so obvious 
in prepuberty. Cools et al. [11] claim that not all germ 
cells expressing foetal antigens are real neoplastic cells 
in very young male patients with undervirilisation. 
In these patients, germ cells may undergo delayed 
maturation, resulting in the prolonged expression 
of such embryonic markers as PLAP, OCT3/4 and 
c-KIT. The location of the germ cells positive for 
these antigens in the centre of seminiferous tubules is 
an additional sign of their immaturity. Normally, the 
gonocytes differentiate into pre-spermatogonia, and 
as part of that process, they move to the basal lamina 
of the seminiferous tubule and stop expression of the 
embryonic genes. Nevertheless, Chemes et al. [8] 
claimed that infantile CIS may have both basal and 
central location because germ cell distribution is not 
yet restricted by a permeability barrier.
The methods used in the present study fulfil the 
required criteria to differentiate normal germ cells 
with delayed maturation and neoplastic CIS cells, 
however, we did not perform the examination of DNA 
ploidy in germ cells, what might eventually confirm 
the results. Chemes et al. [7, 8] note wide cytological 
variation in aneuploid germ cells, ranging from nor-
mal-looking large infantile spermatogonia to gono-
cyte/CIS cells. As the earliest recognizable change in 
germ cell neoplastic transformation is thought to be 
DNA polyploidy of foetal germ cells, so they propose 
careful histopathological examination of cytological 
signs of malignancy, their topographic distribution, 
immunohistochemical markers and the use of DNA 
densitometry to confirm the presence of neoplastic 
tendencies in infantile germ cells. In our previous 
study among 70 patients from various high-risk groups 
of GCT, the incidence of neoplastic lesions was found 
to be the highest in children with GD (43.5%) [39], 
and the aneuploid DNA content, with pattern typical 
of GCT cells, was found in 42–98% of germ cells in 
the dysgenetic testes of prepubertal children [21]. The 
neoplastic transformation of germ cells in the dysge-
netic gonads of prepubertal children was revealed also 
by double immunolabelling with antibodies against 
PLAP and RBM (germ cell-specific RNA-binding 
motif protein encoded by the Y-chromosome) [40, 
41]. The RBM protein is expressed in normal male 
germ cell nuclei of pubertal and adult testis, as well 
as foetal ones from the second trimester of gestation 
[42]. The study demonstrated normal germ cells to be 
RBM-immunopositive, and PLAP-positive germ cells 
to be RBM-immunonegative. 
In other study [9] we found that within a group of 
46 young patients with DSD aged from 3 months to 
19 years the incidence of neoplastic lesions (mostly 
bilateral) was 90.9% in those with partial GD, 76.9% 
(mostly unilateral) in those with asymmetric GD and 
23.1% (unilateral) in those with complete GD. Less 
disturbed testicular organogenesis was found to pre-
dispose the patient more toward germ cell neoplasia. 
Chemes et al. [8] have described the similar findings 
in their recent publication. They suggested that dis-
rupted Sertoli cell function in severe dysgenesis may 
not only fail to elicit gonocyte differentiation but also 
compromise their viability and proliferative capacity. 
This observation was confirmed also in milder forms 
of GD in adult patients [26]. Nevertheless, the results 
of the present study do not indicate significant differ-
ences in the incidence of germ cell lesions in either 
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complete or partial GD, except the finding that the 
neoplastic lesions were found only in underdeveloped 
testes, but not streak gonads, of asymmetric GD.
The present study also indicates that overt GCT 
are more frequent in pubertal/adult patients than in 
prepubertal children (21.3% vs. 2.1%). This confirms 
the observation that GCT predominantly occur from 
puberty, when CIS cells start proliferation and give 
rise to invasive neoplasia [27]. Furthermore, the 
preinvasive germ cell lesions existing in 34.04% (GB 
— 19.1%, CIS — 14.9%) pubertal/adult patients may 
transform into invasive GCT. It has been previously 
revealed that 50% of the testes bearing the precursor 
lesion will progress to invasive cancer within 5 years 
and 70% will do so within 7 years [34]. Moreover, 
increased serum levels of FSH were seen in all pa-
tients from the older subgroup, while LH levels were 
raised and testosterone levels lowered in most of these 
patients. There are suggestions that low testosterone 
secretion and the associated increased secretion of 
gonadotropins may induce the formation or maintain 
neoplastic lesions in dysgenetic testes [16]. Both FSH 
and LH were found to be positively correlated with 
the number of CIS cells in children with GD [43]. 
Other clinical studies have shown that in adult men, 
FSH and LH may influence the number of premeiotic 
germ cells, including CIS cells [44–47]. 
Because of the commonly known high risk of GCT 
occurring in the dysgenetic gonads of patients with 
Y-chromosome after puberty and their poor hor-
monal and gametogenic function, gonadectomy has 
been recommended before puberty [2, 48]. However, 
prophylactic gonadectomy may deprive some boys of 
natural maturation [10], and in some rare cases, their 
chance for fertility [49]. Biopsy of dysgenetic gonads 
in childhood in order to detect neoplastic cells is 
performed rarely (including this study). The biopsy 
is controversial because of the low gonadal volume 
and the potential risk of worsening the function of 
the already compromised testis. However, there are 
suggestions that dysgenetic gonads should be biopsied 
during orchiopexy or genital surgery in DSD children 
[50]. The predictive value of the biopsy sample for the 
further development of neoplastic lesions depends 
on the availability of specific immunohistochemical 
markers, as well as the histological characteristics 
[51]. This enables early diagnosis without overtreat-
ment, such as prophylactic gonadectomy in the case 
of low tumour risk. Moreover, recent reports show 
that testicular biopsy performed in boys does not 
have adverse effects such as antisperm antibodies 
production or testicular microlithiasis in adulthood 
[52]. The prepubertal biopsy of dysgenetic testes 
seems reasonable, because nowadays it is possible 
to apply the methods of assisted reproduction even 
if single spermatids are found intratesticularly [53]. 
Patients with relatively good development of testes 
and preserved hormonal function demonstrated by 
a good response to hCG stimulation (milder forms of 
partial GD) have better prognosis to maintain testi-
cular function in adulthood, however, they are usually 
infertile [54, 55]. In case the premalignant changes 
are found, gonadectomy is recommended [51]. The 
decision may be additionally supported by low testo-
sterone production and low volume of gonads. In adult 
patients with a higher risk of testicular GCT (i.e. DSD, 
undescendent testes, GCT in the contralateral testis) 
it is no doubt that biopsy should be recommended, 
especially, when increased FSH concentration, low 
testicular volume, poor semen parameters and/or 
microcalcifications are found [56]. 
Conclusions
In conclusion, dysgenetic gonads in patients with 
Y-chromosome have a high risk of germ cell neo-
plasia (ca. 50%). If they are preserved until puberty/ 
/early adulthood they may develop overt, invasive 
GCT. The gonads have also poor hormonal activity 
(hypergonadotropic hypogonadism) in most of the 
patients. However, each case must be considered in-
dividually and a decision to remove the gonad or not 
should be based on the comprehensive analysis of the 
phenotype by a multidisciplinary team of specialists 
in consultation with the patient and/or the parents. If 
dysgenetic gonads are not resected in childhood, these 
patients need careful ongoing follow-up examination, 
including biopsy.
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